Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regen BioPharma (RGBP) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Regen BioPharma (RGBP) over the last 11 years, with Q3 2025 value amounting to 207.28%.

  • Regen BioPharma's EBITDA Margin fell 634300.0% to 207.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 143.11%, marking a year-over-year increase of 332600.0%. This contributed to the annual value of 143.11% for FY2025, which is 332600.0% up from last year.
  • Per Regen BioPharma's latest filing, its EBITDA Margin stood at 207.28% for Q3 2025, which was down 634300.0% from 69.0% recorded in Q2 2025.
  • Over the past 5 years, Regen BioPharma's EBITDA Margin peaked at 47.3% during Q1 2021, and registered a low of 785.35% during Q4 2022.
  • Over the past 5 years, Regen BioPharma's median EBITDA Margin value was 144.17% (recorded in 2023), while the average stood at 176.38%.
  • Per our database at Business Quant, Regen BioPharma's EBITDA Margin tumbled by -6051700bps in 2022 and then soared by 5774700bps in 2023.
  • Regen BioPharma's EBITDA Margin (Quarter) stood at 180.18% in 2021, then crashed by -336bps to 785.35% in 2022, then surged by 74bps to 207.88% in 2023, then soared by 50bps to 103.92% in 2024, then crashed by -99bps to 207.28% in 2025.
  • Its last three reported values are 207.28% in Q3 2025, 69.0% for Q2 2025, and 191.91% during Q1 2025.